Research programme: PPAR gamma agonists - SK biopharmaceuticals

Drug Profile

Research programme: PPAR gamma agonists - SK biopharmaceuticals

Alternative Names: YKP4183; YKP4283

Latest Information Update: 28 Sep 2011

Price : $50

At a glance

  • Originator SK Holdings
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 28 Sep 2011 Preclinical development is ongoing
  • 21 Feb 2007 Preclinical development is ongoing
  • 25 Mar 2004 SK Bio-Pharmaceuticals is seeking a partnership for the programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top